Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Kopran Ltd (KOPRAN) is currently trading at 234.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd. Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition. The company has an extensive export reach across over 50 countries and has facilities accredited by international regulatory bodies, underscoring its commitment to maintaining global manufacturing standards. Strategically, Kopran focuses on driving sustainable growth through R&D, capacity expansion, and reducing dependency on imports for intermediates, enhancing domestic self-sufficiency.
Over the past 52 weeks, Kopran Ltd has traded between a low of ₹107.00 and a high of ₹253.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kopran Ltd has a market capitalization of approximately 1,159.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kopran Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 46.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,159.82 Cr, Kopran Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kopran Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kopran Ltd is 46.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Consolidated revenue from operations was ₹153.99 crore and consolidated PAT was ₹6.70 crore for the quarter ended June 30, 2026.
Kopran Limited is an integrated pharmaceutical company engaged in the manufacture and sale of formulations and active pharmaceutical ingredients (APIs) globally, with a focus on quality and technology. They operate two main business verticals through Kopran Limited and Kopran Research Laboratories Ltd.
Kopran has experienced fluctuating financial performance, with revenue from operations in Q3 2025-26 reaching Rs. 19,428 lakhs. However, EBITDA margins have decreased compared to previous years, indicating potential cost pressures or market competition.
The company has an extensive export reach across over 50 countries and has facilities accredited by international regulatory bodies, underscoring its commitment to maintaining global manufacturing standards.
Strategically, Kopran focuses on driving sustainable growth through R&D, capacity expansion, and reducing dependency on imports for intermediates, enhancing domestic self-sufficiency.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,160 Cr
High Risk
46.4
37.7
-1.6
2.2
253.00
107.00
Sales CAGR
Profit CAGR
ROE
Bearish
4
Neutral
5
Bullish
5
ROCE
Bearish
9
Neutral
5
Bullish
32
Bearish
5
Neutral
0
Bullish
27
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
35.15 | 1,321 Cr | 50.21 | 2.53 | 0.29 | 6.52 | 6.49 | 3.13 | ||
637.00 | 1,283 Cr | 13.30 | 1.69 | 0.28 | 11.60 | 15.18 | 10.83 | ||
132.25 | 1,218 Cr | 30.47 | 3.33 | 0.38 | 0.42 | 2.70 | 6.68 | ||
234.00 | 1,160 Cr | 46.41 | 2.19 | 1.25 | 4.85 | 6.56 | 2.75 | ||
333.15 | 1,135 Cr | 49.28 | 2.13 | 0.44 | 8.81 | 10.79 | 1.91 | ||
1532.05 | 1,085 Cr | -36.19 | 3.37 | 0.06 | -2.54 | -1.83 | -4.89 | ||
928.85 | 1,076 Cr | 29.08 | 3.06 | 0.05 | 10.54 | 16.04 | 7.98 | ||
| Median: 7 Co. | — | 333.15 | 1,160 Cr | 30.47 | 2.53 | 0.29 | 6.52 | 6.56 | 3.13 |
